LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Listă Acțiuni・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Închisă

SectorSănătate

66.12 0.18

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

65.34

Maxim

67.23

Indicatori cheie
By Trading Economics
Venit	-317M -142M
Vânzări	98M 452M
P/E Medie Sector	25.027 49.8
Marjă de profit	-31.342
Angajați	423
EBITDA	-3.5M 281M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+40% upside

Dividende
By Dow Jones
Următoarele câștiguri	11 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-1.7B 7.6B
Deschiderea anterioară	65.94
Închiderea anterioară	66.12

Sentimentul știrilor

By Acuity

91%

7 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

60.49 / 70.14 Suport & Rezistență

Halozyme Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 mai 2026, 23:41 UTC

Câștiguri

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 mai 2026, 21:40 UTC

Câștiguri

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 mai 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 mai 2026, 23:13 UTC

Câștiguri

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 mai 2026, 23:13 UTC

Câștiguri

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 mai 2026, 23:12 UTC

Câștiguri

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 mai 2026, 23:11 UTC

Câștiguri

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 mai 2026, 23:07 UTC

Câștiguri

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 mai 2026, 23:06 UTC

Câștiguri

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 mai 2026, 23:06 UTC

Câștiguri

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 mai 2026, 23:05 UTC

Câștiguri

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 mai 2026, 23:04 UTC

Câștiguri

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 mai 2026, 22:50 UTC

Câștiguri

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 mai 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 mai 2026, 22:11 UTC

Câștiguri

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 mai 2026, 22:11 UTC

Câștiguri

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 mai 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 mai 2026, 21:58 UTC

Câștiguri

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mai 2026, 21:47 UTC

Market Talk

Câștiguri

Costco Posts 13% Sales Growth in April -- Market Talk

6 mai 2026, 21:46 UTC

Câștiguri

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 mai 2026, 21:40 UTC

Câștiguri

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mai 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 mai 2026, 21:32 UTC

Acțiuni populare

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 mai 2026, 21:29 UTC

Câștiguri

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Comparație

Modificare preț

Halozyme Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

40% sus

Prognoză pe 12 luni

Medie 90.4 USD 40%

Maxim 96 USD

Minim 75 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHalozyme Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Halozyme Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

60.49 / 70.14Suport & Rezistență

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

7 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.